Literature DB >> 11154273

VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling.

E J Davidowitz1, A R Schoenfeld, R D Burk.   

Abstract

Mutations in the von Hippel-Lindau (VHL) gene are involved in the family cancer syndrome for which it is named and the development of sporadic renal cell cancer (RCC). Reintroduction of VHL into RCC cells lacking functional VHL [VHL(-)] can suppress their growth in nude mice, but not under standard tissue culture conditions. To examine the hypothesis that the tumor suppressor function of VHL requires signaling through contact with extracellular matrix (ECM), 786-O VHL(-) RCC cells and isogenic sublines stably expressing VHL gene products [VHL(+)] were grown on ECMs. Cell-cell and cell-ECM signalings were required to elicit VHL-dependent differences in growth and differentiation. VHL(+) cells differentiated into organized epithelial sheets, whereas VHL(-) cells were branched and disorganized. VHL(+) cells grown to high density on collagen I underwent growth arrest, whereas VHL(-) cells continued to proliferate. Integrin levels were up-regulated in VHL(-) cells, and cell adhesion was down-regulated in VHL(+) cells during growth at high cell density. Hepatocyte nuclear factor 1alpha, a transcription factor and global activator of proximal tubule-specific genes in the nephron, was markedly up-regulated in VHL(+) cells grown at high cell density. These data indicate that VHL can induce renal cell differentiation and mediate growth arrest through integration of cell-cell and cell-ECM signals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11154273      PMCID: PMC86677          DOI: 10.1128/MCB.21.3.865-874.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  41 in total

Review 1.  Molecular basis of autosomal dominant polycystic kidney disease.

Authors:  T Watnick; G G Germino
Journal:  Semin Nephrol       Date:  1999-07       Impact factor: 5.299

2.  The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Authors:  S Koochekpour; M Jeffers; P H Wang; C Gong; G A Taylor; L M Roessler; R Stearman; J R Vasselli; W G Stetler-Stevenson; W G Kaelin; W M Linehan; R D Klausner; J R Gnarra; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

3.  Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.

Authors:  T Kamura; D M Koepp; M N Conrad; D Skowyra; R J Moreland; O Iliopoulos; W S Lane; W G Kaelin; S J Elledge; R C Conaway; J W Harper; J W Conaway
Journal:  Science       Date:  1999-04-23       Impact factor: 47.728

4.  The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2.

Authors:  T Kamura; M N Conrad; Q Yan; R C Conaway; J W Conaway
Journal:  Genes Dev       Date:  1999-11-15       Impact factor: 11.361

5.  The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity.

Authors:  J Lisztwan; G Imbert; C Wirbelauer; M Gstaiger; W Krek
Journal:  Genes Dev       Date:  1999-07-15       Impact factor: 11.361

6.  Abnormal nephron development associated with a frameshift mutation in the transcription factor hepatocyte nuclear factor-1 beta.

Authors:  C Bingham; S Ellard; L Allen; M Bulman; M Shepherd; T Frayling; P J Berry; P M Clark; T Lindner; G I Bell; G U Ryffel; A J Nicholls; A T Hattersley
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

7.  Loss of function of the tissue specific transcription factor HNF1 alpha in renal cell carcinoma and clinical prognosis.

Authors:  A G Anastasiadis; I Lemm; A Radzewitz; A Lingott; T Ebert; R Ackermann; G U Ryffel; W A Schulz
Journal:  Anticancer Res       Date:  1999 May-Jun       Impact factor: 2.480

8.  Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.

Authors:  M Los; S Zeamari; J A Foekens; M F Gebbink; E E Voest
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

Review 9.  Autosomal dominant polycystic kidney disease: clues to pathogenesis.

Authors:  P C Harris
Journal:  Hum Mol Genet       Date:  1999       Impact factor: 6.150

Review 10.  The VHL tumour-suppressor gene paradigm.

Authors:  W G Kaelin; E R Maher
Journal:  Trends Genet       Date:  1998-10       Impact factor: 11.639

View more
  37 in total

Review 1.  Renal cancer: oxygen meets metabolism.

Authors:  Volker H Haase
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

Review 2.  Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Authors:  Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Journal:  Mol Cancer Ther       Date:  2010-11-15       Impact factor: 6.261

3.  Beyond the Knudson's hypothesis in von Hippel-Lindau (VHL) disease-proposing vitronectin as a "gene modifier".

Authors:  Francesco Turturro
Journal:  J Mol Med (Berl)       Date:  2009-06       Impact factor: 4.599

4.  Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation.

Authors:  Qingzhou Ji; Robert D Burk
Journal:  Biochem Cell Biol       Date:  2008-06       Impact factor: 3.626

Review 5.  Novel approaches in the therapy of metastatic renal cell carcinoma.

Authors:  John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Journal:  World J Urol       Date:  2005-04-05       Impact factor: 4.226

6.  Protein tyrosine phosphatase ζ enhances proliferation by increasing β-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.

Authors:  Donghao Shang; Xiuhong Xu; Daye Wang; Yong Li; Yuting Liu
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

7.  The von Hippel-Lindau protein pVHL inhibits ribosome biogenesis and protein synthesis.

Authors:  Wen-Ting Zhao; Cheng-Fu Zhou; Xue-Bing Li; Yun-Fang Zhang; Li Fan; Jerry Pelletier; Jing Fang
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

8.  Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.

Authors:  Sergey V Ivanov; Alla V Ivanova; Konstantin Salnikow; Olga Timofeeva; Malayannan Subramaniam; Michael I Lerman
Journal:  Biochem Biophys Res Commun       Date:  2008-03-24       Impact factor: 3.575

9.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

10.  Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization.

Authors:  Qiliang Cai; Erle S Robertson
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.